ArticleLab animal2026
Exploration of refined humane endpoints for melioidosis in BALB/c mice.
Article in Lab animal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The development of humane endpoints is critical for refining scientific studies involving animals. Body weight and clinical signs of disease data collected in four recent studies assessing medical countermeasures for utility against the disease melioidosis in mice were further analyzed. Here we used this information to ascertain whether a suitable alternative humane endpoint could be identified. A total of 66 possible alternative humane endpoints were explored, which varied the threshold values of the 'percentage body weight loss post-challenge' and 'the clinical signs over time' following cessation of treatment. The findings indicated a suitable alternative endpoint of a percentage weight loss threshold of 25%, and/or using an average total clinical signs score ≥5 over a 48-h period. This endpoint resulted in a sizeable reduction in median 'sign-days' (total clinical score multiplied by the number of days remaining in study) per mouse of 21 days (ranging from 8 to 56 between studies), while maintaining 100% sensitivity and 93% specificity (ranging from 79% to 97% between studies). In addition, the risk of altering the scientific outcome of each study remained low when utilizing this new endpoint. In conclusion, current humane endpoints in this setting can be refined without negatively impacting the key study findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.